Protocol for study of financial incentives for smoking cessation in pregnancy (FISCP): randomised, multicentre study

perinatal and postnatal adverse health outcomes[7 8] such as spontaneous abortion, premature birth and low birth weight. Recent studies have also highlighted its long-lasting effects on health outcomes of the offspring.[9–15] MSDP may increase the risk of psychiatric comorbidity, obesity, asthma and type 2 diabetes. It increases all-cause mortality among offspring.[7] Cohort studies have reported that smoking in pregnancy is associated with increased risk of childhood retinoblastoma,[16] brain tumours,[17] and leukaemia and lymphoma.[18 19]

The last French perinatal survey[20] reports that, in 2010, 30.5% of pregnant women (total sample 13 888) were smokers before pregnancy, and ~20% of the total smoked at least 10 cigarettes per day. In 2010, 17% of pregnant women smoked in the last trimester, which corresponds to 137 180 fetuses exposed in utero to active smoking in the last trimester (802 224 births in 2010[21]).

To the best of our knowledge, no national data exist on: how many women stop smoking before pregnancy and maintain full abstinence during fertilisation, the first and second trimester, and up to and during delivery; how many smoking women abstain partially during pregnancy and at the time of delivery; and how many relapse, and at what point, after giving birth. Most pregnant smokers reduce their consumption during pregnancy or smoke intermittently, and, if they quit, most of them relapse after delivery,[22–25] which is a main concern because of postnatal second-hand smoke exposure of the newborn/infant/child. The relapse rate varies according to the country. As for other behavioural data influenced by cultural, socioeconomic and genetic factors, issues concerning smoking during and after pregnancy are not automatically transposable to the population of French pregnant smokers.

Nicotine replacement therapies (NRTs) are considered to be the cornerstone intervention to help smokers quit. Their efficacy has been demonstrated in various populations of smokers.[26] In pregnant smokers, NRTs are still recommended by French health authorities,[27] but, because of the lack of conclusive evidence on their efficacy for smoking cessation among pregnant women, recommendations in the UK are more cautious,[28] and NRTs are not recommended in US guidelines.[29] Previous trials,[30–34] two meta-analyses[35 36] and one sufficiently powered UK study[37] concluded that NRTs are not effective in helping pregnant smokers stop smoking. A French multicentre, randomised, parallel group, national study found that NRTs, even when adjusted for nicotine uptake by smoking and when administered at higher than usual doses of nicotine, do not result in higher abstinence rates than placebo.[38] The most recent Cochrane meta-analysis concluded that, when all NRT trials in pregnancy were taken into account, NRT use can be associated with an increased rate of abstinence in late pregnancy; however, when non-placebo-controlled and potentially biased trials were excluded, placebo-controlled randomised trials did not show efficacy of NRT use over placebo.[39] Furthermore, there is no evidence that NRTs in pregnancy have either benefit or adverse effect on birth outcomes.[39]

Contingency management interventions, such as providing tangible rewards for cigarette abstinence, are an alternative to NRTs.

FINANCIAL INCENTIVES AND TOBACCO CONSUMPTION

The theoretical framework of the economics of smoking[40 41] provides several mechanisms to explain tobacco consumption and potential instruments for policy interventions. According to Grossman's model of health capital[42] and Becker and Murphy's model of rational addiction,[43] smoking is the result of a bargain between the present satisfaction induced by tobacco consumption and the direct costs of tobacco, delayed losses induced by future tolerance, and potential losses in health capital. If the demand for tobacco is elastic to price variation, taxation is thus a natural incentive instrument for reducing tobacco consumption by increasing direct costs. This instrument has been shown to be efficient for reducing smoking initiation and for increasing tobacco cessation among pregnant women as well as in the general population of smokers.[44] Despite tobacco taxation, the proportion of smokers remains higher in low-income than in high-income groups. While an increased price through taxes diminishes tobacco consumption among low-income individuals, it also raises equity concerns, as spending on tobacco has more weight in the budget of the low-income individual than in that of the high-income individual. In addition, it is difficult to implement for a targeted subpopulation.[45 46]

The updated meta-analysis of studies of financial incentive interventions in smoking cessation in the general population of smokers has shown that they increase cessation rates while they are in place.[47] The meta-analysis of eight studies from the USA and UK among pregnant smokers provided an OR of 3.60 (95% CI 2.39 to 5.43) favouring financial incentives over control conditions.[47] Although evidence is growing to support the efficacy of fi

The main outcome measure was point prevalence abstinence at gestational weeks 34–38 verified by saliva or urinary cotinine. More pregnant smokers stopped smoking in the IG than in the CG (22.5% vs 8.6%; absolute risk difference 14% (95% CI 8.2% to 19.7%)). There was no difference in birth weight of their offspring (3140 g, SD=600 vs 3120 g, SD=590).

The efficacy of financial incentives in helping pregnant smokers quit smoking has never been investigated in the French context. Because of cultural, economic and other individual and contextual differences, results from other countries cannot be directly applied to French pregnant smokers.

BEHAVIOURAL CHARACTERISTICS AND SMOKING IN HEALTH ECONOMICS

According to the seminal framework of behavioural economics of smoking,[40 51 52] time preferences are defined by how individuals weight future events when a decision involves delayed costs or benefits as well as present ones. The way individuals value time may affect present-day health decisions.

Experimental and health economic studies have reported that present-oriented individuals are more likely to be smokers than forward-looking ones, since present-oriented individuals overvalue the short-term satisfaction derived from smoking compared with future harmful consequences of tobacco smoking.[41] On the basis of subjective scales introduced in the 2008 French National Health, Health Care and Insurance Survey (ESPS), Jusot and Khlat[53] found that being present-oriented is associated with current smoking, even after adjustment for education. Regarding quitting behaviours, Brown and Adams[54] provided evidence from Australian data that more-forward-looking individuals are more likely to quit smoking. A study based on the 2004 wave of the ESPS survey by Grignon[55] reported that present-oriented individuals are more likely to quit after more failed attempts and at an older age.

The way individuals value risky outcomes—referred to as risk preference—may influence their likelihood of smoking. Empirical studies have found a negative relationship between risk aversion and tobacco use.[53 56]

The health psychology literature explains smoking cessation by various psychological determinants such as self-efficacy (ie, confidence in one's ability to abstain), impulsivity, locus of control, and personality traits. Self-efficacy is a determinant of smoking cessation in the sense that it is related to the likelihood of initiating and maintaining an effort and being able to cope with highly tempting situations (for a meta-analysis, see Gwaltney et al[57]). Since self-efficacy evolves during the cessation process, it needs to be assessed continuously during an intervention.

Choice impulsivity involves the preferential selection of smaller–sooner rewards over larger–later rewards.[58] Hence, smokers choose the immediate benefits of cigarettes over a healthier future life. This attitude is usually associated with drug- and non-drug-related (eg, pathological gambling) addictions. Several studies have reported higher levels of impulsivity in smokers than in non-smokers.[59] Impulsivity usually also predicts a shorter time of relapse because impulsive individuals are supposed to be more sensitive to smoking cues.[60]

Locus of control is related to the extent to which individuals believe that they can control what happens to them. The locus of control is to some degree internal (the individual believes she controls her life) or external (she believes that luck, fate or powerful others control her life). Abstinence from smoking is associated with an internally focused locus of control, such that individuals who perceive themselves as controlling life events are more likely to quit smoking.[59]

Personality traits from the five-factor model[61] (openness, conscientiousness, extraversion, agreeableness, neuroticism) have been shown to be associated with tobacco consumption. A meta-analysis[62] has shown an association between smoking and low conscientiousness, low agreeableness and high neuroticism. Neuroticism is related to smoking, especially among individuals with low conscientiousness. Openness is significantly associated with motivation to quit and the number of quit attempts of 24 hours during the past year.[63]

Financial incentives may be especially efficient among women with particular socioeconomic and behavioural characteristics; they are expected to be particularly efficient among disadvantaged women who have a higher marginal utility of consumption than more advantaged ones. Similarly, providing immediate rewards for behaviour changes may help to reduce the effect of some behavioural characteristics such as immediacy and time preference. For instance, financial incentives may be more effective among present-oriented women who overvalue short-term satisfaction of smoking compared with future harmful consequences of tobacco smoking. Immediate financial incentives may neutralise the short-term benefit of smoking by increasing the short-term benefit of smoking cessation.

OBJECTIVES

The main objective of this study is to assess the efficacy of financial incentives on smoking abstinence rate among French pregnant smokers.

Secondary objectives include exploration of predictors of response to financial incentives such as socioeconomic status, social background, smoking characteristics, locus of control, impulsivity, self-efficacy, personality traits, and time and risk preferences, in order to determine profiles of women who could be efficiently targeted by this kind of intervention. Further objectives include: (a) a cost–benefit analysis based on the cost of pregnancy-related and infant-disease-related costs due to MSDP with respect to the cost and benefit of using financial incentives; (b) an assessment of selection bias from agreeing to being

part of the study or not by comparing women who gave their consent to participate in the study and women who did not.

METHODS AND ANALYSIS

Design

This will be a single-blind, randomised, two parallel groups, national superiority trial run in 16 maternity wards all over France. A total of 398 pregnant smokers will be randomised (1:1 ratio) to the intervention (N=199) and control (N=199) groups.

Participants

Consent

Participants' written consent will be obtained by the investigators. In order for birth outcome data to be collected, participants will sign a statement to the effect that they are not opposed to recording of birth outcome data on the child to be born. These original documents will be archived by the investigators in their respective maternity wards.

Inclusion criteria

1. Pregnant women motivated to quit smoking (score higher than 5 on a visual analogue scale ranging from 0 (not at all motivated) to 10 (extremely motivated)).
2. 18 years old or older.
3. Smoking at least five cigarettes per day or three roll-your-own cigarettes per day.
4. Pregnancy of <18 weeks of amenorrhoea (WA).
5. Affiliated to National Health Insurance funds or to another medical health insurance fund as required by French law on biomedical research.
6. Having signed an informed written consent form
7. Agreeing to collection of birth characteristics of the child to be born.

Exclusion criteria

1. Current treatment for a chronic psychiatric disorder using neuroleptics, antidepressants or anxiolytics.
2. Use of tobacco products other than cigarettes.
3. Use of either bupropion or varenicline because their use is contraindicated in pregnancy.
4. Because of the lack of knowledge on the health benefit–risk ratio of electronic cigarettes,[64] electronic cigarette users will be excluded.

NB Multiple pregnancies will not be an exclusion criterion.

Setting and recruitment

Participants will be recruited, included and followed-up in 16 maternity wards in France. The 16 centres are expected to include 20–30 smoking pregnant women every month. Assuming that each centre will randomise 15 women per year, we will be able to recruit 240 women per year.

Participants will be recruited by word of mouth, flyers and advertisements in pharmacies, local radio broadcasts, local newspapers, general practitioner offices and in the participating maternity wards. After a phone interview for eligibility, pregnant smokers will be invited to attend the closest maternity ward for a screening visit.

Investigators will be midwifes or physicians who routinely treat pregnant smokers. They should all have obtained a smoking cessation specialist diploma and should be familiar with smoking cessation issues among pregnant smokers.

Randomisation

A computer-generated randomisation list in blocks of four will be prepared by a statistician who is independent of the study. The randomisation list by centre will be incorporated into the electronic case report form (eCRF). A randomisation number will be allocated at the first visit after the participants' characteristics have been checked for inclusion/exclusion criteria and their written informed consent obtained.

Interventions

During each visit, each woman will benefit from a short intervention for smoking cessation according to nationally accepted guidelines whatever the study group they belong to. It will include motivational counselling, support and skill-training elements.[65 66]

All necessary care and interventions will be permitted during the trial.

Chronology of the trial

A quit date will be set at randomisation. The quit date should occur between randomisation and day 14. Monthly face-to-face visits will be planned. The total number of visits will depend on the date of delivery. For example, if the quit date is at 12 WA and delivery at 40 WA, monthly visits will be carried out at WA 16, 20, 24, 28, 32 and 36 (six visits); if the quit date is at 16 WA and delivery at 34 WA, four visits will be conducted (WA 20, 24, 28 and 32). The number of visits determines the amount of monetary rewards earned for attending the visits in both groups. The total duration of participation in the study will be 12 months on average: ~6 months until giving birth and a follow-up phone call 6 months after birth.

In cases of missed visits, participants will be called by telephone at least twice, followed, in the case of non-response, by regular mail to encourage them to attend the next visit.

Incentives for abstinence

Monetary reward for abstinence will be given through vouchers (Kadeos http://www.edenred.fr/besoin/avantages-aux-salaries/produit/ticket-kadeos/) that can be redeemed in many different shops and superstores; they cannot be used to buy tobacco or alcohol products. The value of each voucher will be €20. Participants in both control

and intervention groups will receive a €20 voucher as a show-up fee for completing the visit.

Intervention group (IG)

Every participant can earn additional vouchers conditional on her abstinence. For example, if the participant has abstained during five consecutive visits, she can earn up to €380 of vouchers.

Figure 1 shows the payoff tree (in euros) that a participant can earn according to her group and abstinence, under the assumption that she attends five visits.

In the IG, the payoffs are based on two principles: the reward for abstinence today and the reward for continuous (past) abstinence. Hence, the payoff increases with the number of times a participant has been abstinent but also with the number of successive abstinences.

If the participant is not abstinent ($\bar{A}$), she gets a €20 voucher as a show-up fee. If she is abstinent (A), she earns the show-up fee and an additional amount to reward her abstinence. If she is abstinent at the first post-quit day visit she will be rewarded with an additional €40 of vouchers. This amount then increases by €20 progressively if she remains abstinent for the next visits (€60, €80 and €100). If a participant has been abstinent and then non-abstinent, the next time she is abstinent, the last abstinent payment will recur in order to reward her abstinence and avoid penalty for the previous non-abstinence. This feature also helps to reduce no-show, especially if the participant has been abstinent. Table 1 refers to four different scenarios of financial incentives (in euros) according to the abstinence of the participant over five visits.

If a participant does not show up for a visit but shows up for the next visit, the no-show-up visit will be considered to be a non-abstinence visit, and therefore when she shows up at the next visit, the financial incentive will be that of the last show-up visit.

A general expression allows us to determine the total payoffs after the total number of visits, T, according to each situation. Let Y_T^{IG} be the total payoff after T visits in the IG

$$Y_T^{IG} = 20 + [40 \cdot N_2^A \cdot I_2^A + 20] + \sum_{t=3}^{T}(20 \cdot I_t^A \cdot (N_t^A + 1) + 20)$$

$$\text{for} \quad t = \{3, \dots, T\}$$

The first visit is the inclusion and randomisation visit in both groups and everyone receives €20. N_t^A is the number of successive times a pregnant woman has been abstinent, measured at visit t. I_t^A is a dummy variable, which is equal to 1 if the pregnant woman is abstinent at visit t, and is equal to 0 otherwise.

Control group (CG)

Participants randomised to the CG will receive a €20 voucher at the end of each completed visit as a show-up fee, but in contrast with the IG, abstinence will not be rewarded. The total payoff will be a function of the total number of visits the participant attended.

Figure 1

Table 1

Scenario for 5 visits	R=V1 (€)	V2	V3	V4	V5	Total gain
1.	20	$A_2=1,\ A_2=1$ $40 \times 1 \times 1 + 20 = 60$	$A_3=1,\ A_3=2$ $20(2+1)1+20=80$	$A_4=1,\ A_4=3$ $(20(3+1)1+20)=100$	$A_5=1,\ A_5=4$ $(20(4+1)1+20)=120$	20+360
2.	20	$A_2=1,\ A_2=1$ $40 \times 1 \times 1 + 20 = 60$	$A_3=1,\ A_3=2$ $20(2+1)1+20=80$	$A_4=0,\ A_4=2$ $(20(2+1)0+20)=20$	$A_5=0,\ A_5=2$ $(20(2+1)0+20)=20$	20+180
3.	20	$A_2=1,\ A_2=1$ $40 \times 1 \times 1 + 20 = 60$	$A_3=0,\ A_3=1$ $(20(1+1)0+20)=20$	$A_4=1,\ A_4=1$ $20(1+1)1+20=40$	$A_5=0,\ A_5=1$ $(20(1+1)0+20)=20$	20+160
4.	20	$A_2=0,\ A_2=1$ $40 \times 1 \times 0 + 20 = 20$	$A_3=1,\ A_3=1$ $(20(1+1)1+20)=40$	$A_4=1,\ A_4=2$ $20(2+1)1+20=60$	$A_5=0,\ A_5=2$ $(20(2+1)0+20)=20$	20+180

$$IG_T = 20 + [40\, A_2 A_2 + 20] + \sum_{t=3}^{T}(20\, A_t(A_t+1)+20) \qquad = \{3,\ldots,\ \}.$$

6

Hence, the total payoff for participants in the CG is

$$Y_T^{GC} = 20 \cdot t, \quad \text{for} \quad t = \{1, \ldots, T\}$$

Outcomes

Main outcome measure

The main outcome measure will be the continuous smoking abstinence from the predefined quit date until the last predelivery visit.

Previous studies were mainly interested in whether smoking reduction is associated with reduced birth weight. Two earlier studies[67 68] reported that smoking reduction among pregnant smokers had no impact on birth weight. Two subsequent studies[69 70] have shown that reduced cigarette consumption decreased but did not nullify smoking-related loss in birth weight. At the public health level, even a small reduction in a population's birth weight may have long-lasting consequences for the offspring. Continuous abstinence since quit date has a higher likelihood of suppressing smoking-related loss in birth weight than smoking reduction. For this reason, continuous abstinence since quit date has been chosen as the main outcome measure.

Secondary outcome measures

For mothers:
- Point prevalence abstinence at visits defined as self-reported no smoking in the last 7 days and expired air carbon monoxide ≤8 ppm.
- Time (days) to first cigarette after quit date (lapse (a few puffs) or relapse).
- Total number of cigarettes smoked per day.
- Craving to smoke and withdrawal symptom scores.

For newborns:
- Birth weight and other birth characteristics such as head circumference, length, Apgar score at 5 min.
- Gestational age at birth.
- Assessment of intrauterine growth restriction calculated by AUDIPOG (http://www.augipog.net), a national network of intrauterine growth data.

Negative health outcomes during pregnancy (maternal and fetal) and at birth will be recorded from clinical charts.

Power calculation

A previous study[38] that compared nicotine patches with placebo patches in pregnant smokers has shown a continuous abstinence rate of 5.5% in the nicotine group vs 5.1% in the placebo group. Some 53% of women in the nicotine group did not show up for every visit compared with 62% in the placebo group. In Tappin et al,[50] more smokers who were provided with financial incentives (22.5%) had stopped smoking than in the non-incentivised group (8.6%). It is noteworthy that, in this study, the main outcome measure was point prevalence abstinence at 34–38 WA and not continuous abstinence as in the present study.

α	1−β	N for control group	N for intervention group
1:1			
1.		25%	10%
0.05	0.90	133	133
0.05	0.85	114	114
0.05	0.80	100	100
2.		20%	10%
0.05	0.90	266	266
0.05	0.85	228	228
0.05	0.80	199	199

Table 2

The power calculation is based on the main outcome measure. We assume that the abstinence rate among pregnant women will be 10% in the CG and either 25% or 20% in the IG, as presented in table 2. We hypothesise a 10% continuous abstinence rate, double that previously observed[38] in the CG because of the financial reward of showing-up, which may in itself increase the abstinence rate by increasing show-ups. According to table 2, assuming a 20% abstinence rate in the IG, a conservative approach, with an α=0.05 and 1−β=0.80, we would need to randomise 199 women to each group.

In Tappin et al,[50] the lost-to-follow-up rate is 14% and 15% at the primary end point of gestational weeks 34–38. Because of the high frequency (monthly) of face-to-face visits and because show-ups are rewarded with €20, we assume an overall dropout rate of 5%, implying that we would need to randomise 420 pregnant smokers. We assume that approximately 40 women by group will not show up for the first visit, and as a consequence, we expect to recruit between 460 and 480 women who signed the informed consent forms to finally randomise 420.

Independent variables

1st visit:
- Demographic, socioeconomic, obstetric and smoking characteristics
- Age
- Household income
- Self-reported ethnic origin
- Medical, psychiatric history
- Obstetric history: number of previous pregnancies, abortions, miscarriages, deliveries, premature delivery, number of children
- Weeks of amenorrhoea
- Smoking history and characteristics
  - Age smoked first cigarette
  - Partner's smoking
  - Second-hand smoke exposure

- – Number of cigarettes smoked during the last 7 days
- – Fagerström Test for Cigarette Dependence[71]
- – Craving for tobacco using French Tobacco Craving Questionnaire (FTCQ-12)[72]
- – Withdrawal Symptoms Questionnaire[73 74]
- – Expired air CO concentration (Smokerlyzer; Bedfont, Maidstone, Kent, UK)
- – Cannabis consumption in the last 30 days
- ► Alcohol consumption in the last 30 days
- ► Evaluation of alcohol dependence (CAGE questionnaire)[75]
- ► Current use of psychotropic medications
- ► Weight (kg) and height (cm)
- ► Sitting systolic and diastolic blood pressure

Behavioural measures:

- ► Time preferences: the subjective scale from ESPS and the scale for consideration of future consequences (validated measure in French)[53]
- ► Risk preferences: a subjective scale tested and validated in the ESPS survey which measures the willingness to take risks. We will also use a measure developed by Dohmen *et al*,[76] which measures risk aversion in domain-specific risks (financial, health, social)
- ► Impulsivity: Barratt Impulsivity Scale[77]- validated French version[78]
- ► Locus of control: Fetal Health Locus of Control (FHLC) created and validated by Labs and Wurtele.[79] To guarantee validity, this measure will be administered twice: once at inclusion (visit 1) and once halfway through the study (visit 3)
- ► Big Five personality test:[60 78] a short (<1 min to complete) assessment of personality traits, such as extraversion, conscientiousness, agreeableness, neuroticism and openness to experience

A urine sample will be collected to quantify concentration of anabasine, anatabine and cotinine. The justification for this is as follows. Nicotine accounts for ~85–95% of the alkaloid content of tobacco, while anabasine and anatabine are among the most abundant minor tobacco alkaloids.[80 81] Owing to the relatively short elimination half-life of nicotine (about 2 hours), investigating nicotine metabolites that exhibit a longer half-life is a prerequisite to providing relevant information on tobacco consumption. Cotinine is the main metabolite of nicotine whose mean elimination half-life can be shorter during pregnancy. Tobacco use increases the urinary concentration of all three compounds. Complete abstinence from tobacco or no use of NRTs is associated with <3 ng/mL urinary anabasine and <10 ng/mL urinary anatabine. The measure of non-nicotinic alkaloids allows us to distinguish no tobacco use from NRT use, which is associated with urinary cotinine concentration >10 ng/mL. A pregnant woman will therefore be considered not to be smoking and not receiving NRT if she reports no smoking and her expired air CO is ≤8 ppm, her urinary anabasine is ≤3 ng/mL and her urinary cotinine is ≤10 ng/mL. Because anatabine's cut-off values are less well established, its determination will not be used in the primary assessment of abstinence. Quantification of the three compounds in urine samples will be performed by ultra-high performance liquid chromatography coupled with tandem mass spectrometry after a dedicated sample preparation procedure.[82 83]

Follow-up visits: 2nd to last visit (visit 5 or 6):

- ► Self-reported smoking status (abstinent or not) and expired air CO
- ► Number of cigarettes smoked in the last 7 days
- ► Use of NRT: type and daily dose
- ► Use (or not) of an electronic cigarette
- ► FTCQ-12
- ► Withdrawal Symptoms Questionnaire
- ► Cannabis consumption in the last 30 days
- ► Alcohol consumption since last visit: Yes/No
- ► Weight
- ► Sitting systolic and diastolic blood pressure
- ► Any negative health event related or not to the pregnancy. At visit 3, participants will be asked to complete a short questionnaire including the FHLC
- ► Urine sample: as mentioned above, one urine sample will be collected during the inclusion visit (visit 1). A second sample will be randomly collected at visit 2, 3 or 4 according to a random list included in the eCRF. The post-quit day urine sample will allow us to control for self-reported abstinence

Postpartum follow-up: 6 months:

Participants will be contacted 6 months after delivery for a phone innclud2.3579uo the ⑥4 a

Smoking relapse or multiple missed visits will not be a criterion for dropout. Participation in the study ends if pregnancy ends (delivery or any other reasons such as miscarriage). Data of a participant who withdraws her consent to participate will not be included in the ITT database.

Main analysis

The main outcome measure for the mother will be complete continuous abstinence since the quit date, which will be defined as abstinence at each visit (self-reported abstinence during the last 7 days and expired air CO ≤8 ppm) from randomisation to delivery (ie, last study visit before delivery). Abstinence rates will be compared between the intervention and control groups using Fisher's exact test.

Secondary analyses

Relapse to smoking will be described by Kaplan–Meier curves and compared with the log-rank test.

Multivariate analyses will be performed to evaluate the determinants of continuous abstinence since quit date to delivery. Control variables for the intervention effect will be the sociodemographic, tobacco-related, psychological and behavioural characteristics, duration and total dose of NRTs, and centres.

The analysis will include interacting subgroup characteristics such as, for instance, how this probability varies for low and highly educated women who are strongly present-oriented.

The first questionnaire that will be filled in by women taking part in the study and those who do not will provide an insight into the selection bias to participate in the study.

No interim analysis is planned. Unlike medications, financial incentives—the intervention assessed by this trial—cannot lead to premature stopping of the study because of adverse health outcomes.

Sensitivity analyses

1. Differences between intervention and control groups for both main and secondary outcomes will also be analysed according to biochemical verification of abstinence based on negative anabasine, self-report of no smoking, and expired air CO ≤8 ppm.
2. A second sensitivity analysis of effi

Coordinating Centre Members: Chair, Ivan Berlin; data management, Leontine Goldzahl; medicoeconomics, Noémi Berlin and Florence Jusot; monitoring and administration, Jessica Palmyre, France Boyaud and Shoreh Azimi.

No drug safety monitoring committee will be established.

ETHICS AND DISSEMINATION

As dictated by French law on biomedical research, all participants can withdraw from the study at any time and without any justification. The research protocol was approved by the ethics committee (Comité de Protection des Personnes, CPP) of the Pitié-Salpêtrière Hospital on 15 May 2015. Amendment No 1 was approved on 13 July 2015. A consent form in French is available upon request.

Results will be presented at scientific meetings. The authors commit themselves to publish all results of this study in medical, health economic or other scientific journals. The data will be the property of the sponsor, the Assistance public-Hôpitaux de Paris (APHP). The disposition of data sharing and data deposition will be defined by the sponsor.

REFERENCES

1. ... *Health Econ* 2013;22:1470–95.
2. ... *J Health Econ* 2011;30:811–31.
3. ... *Proposition pour une nouvelle politique de lutte contre le tabac.* 2012.
4. ... *Rapport d'information sur l'évaluation des politiques publiques de lutte contre le tabagisme.* 2013. ... /14/ / 0764.
5. ... *Rapport d'évaluation des politiques de lutte contre le tabagisme.* ... 2012.
6. ... OFDT ... 2015-04.
7. ... , et al. ... *Scand J Public Health* 2006;34:660–4.
8. ... , et al. ... *Dev Psychopathol* 2012;24:1377–90.
9. ... 2014. ... /50- ... (... 2015).
10. ... 30- ... *Am J Psychiatry* 2003;160:1978–84.
11. ... , et al. ... *Arch Gen Psychiatry* 2010;67:841–9.
12. ... , et al. ... *Pediatrics* 2012;129:735–44.
13. ... *Int J Obes* 2008;32:201–10.
14. ... 2010:205–10.
15. ... , et al. ... *Biomarkers* 2009;14(=1):97–101.
16. ... *Cancer Causes Control* 2009;20:1551–8.
17. ... , et al. 1.4 ... *Cancer Causes Control* 2004;15:997–1005.
18. ... 1,440,542 ... *Cancer Epidemiol Biomarkers Prev* 2004;13:1528–33.
19. ... *Front Oncol* 2012;2:151.
20. ... 2010 ... 2003 ... 5 2015).
21. ... 2010. ... 20101 (... 1 2016).
22. ... , et al. ... *Eur J Public Health* 2001;11:334–9.
23. ... , et al. ... *Birth* 2007;34:245–52.
24. ... *ScientificWorld Journal* 2012;2012:154910.
25. ... , et al. ... *Addiction* 2016;111:981–90.
26. ... , et al. ... *Cochrane Database Syst Rev* 2012;(11): 000146.
27. ... ( ) ... %28 %29 (9 2015).
28. ...

29. ... (... 19 ... 2016).

... 2008 ...
...08 ...://... ...
...08 (... 9 ... 2015).

30. ... *et al.* ... *Obstet Gynecol.* 2000;96:967–71.

31. ... *Curr Ther Res Clin Exp* 2001;62:274–8.

32. ... *Addict Behav* 2006;31:641–8.

33. ... *et al.* ... *Am J Prev Med* 2007;33:297–305.

34. ... *et al.* ... *Obstet Gynecol* 2008;112:859–67.

35. ... *et al.* ... *Addiction* 2011;106:52–61.

36. ... *et al.* ... *Cochrane Database Syst Rev* 2012;(9): 010078.

37. ... *et al.* ... *N Engl J Med* 2012;366:808–18.

38. ... *BMJ* 2014;348: 1622.

39. ... *et al.* ... *Cochrane Database Syst Rev* 2015;(12): 010078.

40. ... *Handb Heal Econ* 2000;1:1539–627.

41. ... *Handb Heal Econ* 2011;2:95–199.

42. ... *J Polit Econ* 1972;80:223–55.

43. ... *J Polit Econ* 1988;96:675–700.

44. ... *Quest. d'économie la santé* 2012;182:1–8.

45. ... *Économie publique/Public Econ* 2003;13:3–28.

46. ... *J Policy Anal Manag* 2008;27:376–400.

47. ... *Cochrane Database Syst Rev* 2015;(5): 004307.

48. ... *Curr Addict Rep* 2016;3:9–18.

49. ... *et al.* ... *Cochrane Database Syst Rev* 2009;(3): 001055.

50. ... *et al.* ... *BMJ* 2015;350: 134.

51. ... *Q J Econ* 2001;116:1261–303.

52. ... *J Health Econ* 2007;26:927–49.

53. ... *Addict Behav* 2013;38:2167–73.

54. ... *Addiction* 2013;108:186–92.

55. ... *J Socio Econ* 2009;38:739–51.

56. ... *J Health Econ* 2008;27:1260–74.

57. ... *et al.* ... *Psychol Addict Behav* 2009;23:56–66.

58. ... *et al.* ... *Personal Disord* 2015;6:182–98.

59. ... *Psychopharmacology* 1999;146:455–64.

60. ... *et al.* ... *Nicotine Tob Res* 2004;6:641–7.

61. ... *J Pers Soc Psychol* 1987;52:81–90.

62. ... *J Drug Educ* 2006;36:47–58.

63. ... *Addiction* 2004;99:472–81.

64. ... Rapport de l'OMS (2014). ...://... ... 6/ ... 6 10...

65. ... Conférence de consensus. Grossesse et tabac. (2004). ...://... (... 3 ... 2016).

66. ... ...://... /30000/ /2014/ (... 3 ... 2016).

67. ... *Br J Obstet Gynaecol* 1987;94:295–300.

68. ... *J Clin Epidemiol* 1988;41:483–9.

69. ... *et al.* ... *JAMA* 1993;269:1519–24.

70. ... *Nicotine Tob Res* 2013;15:685–92.

71. ... *Nicotine Tob Res* 2012;14:75–8.

72. ... *Nicotine Tob Res* 2010;12:500–7.

73. ... *Arch Gen Psychiatry* 1986;43:289–94.

74. ...://... (... 3 ... 2016).

75. ... *JAMA* 1984;252:1905–7.

76. ... *et al.* ... *J Eur Econ Assoc* 2011;9:522–50.

77. ... *J Clin Psychol* 1995;51:768–74.

78. ... *et al.* ... (-10)./ (-10). *Can J Psychiatry* 2000;45:156–65.

79. ... *J Consult Clin Psychol* 1986;54:814–19.

80. ... *Pharmacol Rev* 2005;57:79–115.

81. ... *et al.* ... *Lancet Oncol* 2008;9:667–75.

82. ... *J Chromatogr A* 2010;1217:7528–38.

83. ... *et al.* ... *Forensic Sci Int* 2011;213:73–84.

84. ... *AIDS Care* 1995;7:55–69.

85. ... *et al.* ... *Addiction* 2016;111:360–70.